AzTrials
AzTrials

CirrhosisNCT04940416

Eye Movement Testing for Diagnosing Encephalopathy in Patients With Liver Disease

An observational study of Cirrhosis and Hepatic Encephalopathy, run by Stanford University at 1 site in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

This study involves utilizing a noninvasive computer application (Neurofit) that performs oculometric assessment of dynamic visual processing in patients with liver cirrhosis to see if the presence of advance liver disease influences eye movement metrics. Read more about this study

Who is it for?
Ages 18 to 65 yearsHealthy volunteers can take part
Conditions the study is for
Cirrhosis, Hepatic Encephalopathy
What is being tested?
Neurofit (oculometric testing)
Type of treatment
Medical device
How many people
48 participants
Where
1 siteUnited States
Study dates
31 Aug 2017to 17 Jun 2021
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: The study population will include consenting patients with cirrhosis seen in the gastroenterology and hematology clinic of the Stanford hospital. They will include patients with cirrhosis of varying severity. The non cirrhosis arm will include patients in the general gastroenterology clinic with no laboratory or radiological evidence of cirrhosis.

Who may be able to join

  • Patients with cirrhosis with clinical appointments in the pretransplant liver clinic
  • Patients in the general gastroenterology clinic without a diagnosis of cirrhosis (controls)

Who cannot join

  • Individuals <18 years
  • cirrhotic patients with hepatocellular cancer
  • individuals with uncontrolled neuropsychiatric illnesses or overt hepatic encephalopathy
  • ongoing alcohol or illicit substance use
  • non-English speakers, as the language barrier may impact psychometric test results

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Stanford University School of Medicine

    Redwood City, California, 94063

Other trials in United States

About this study

Official title: Oculometric Testing for the Diagnosis of Covert Hepatic Encephalopathy

This study involves utilizing a noninvasive computer application (Neurofit) that performs oculometric assessment of dynamic visual processing in patients with liver cirrhosis to see if the presence of advance liver disease influences eye movement metrics.

Read the detailed description

Cirrhosis is an increasingly prevalent medical condition in the United States that impacts health-related quality of life, healthcare resource utilization and survival. Patients with decompensated cirrhosis occasionally suffer from hepatic encephalopathy which is a serious complication that results from portosystemic shunting of blood leading to a spectrum of neuropsychiatric changes and alteration in consciousness levels when it becomes overt (overt hepatic encephalopathy, OHE).

Hepatic encephalopathy affects 30-45% of patients with cirrhosis and its occurrence and progression is associated with higher mortality.

In particular, Hepatic encephalopathy (HE) is an independent predictor of hospital readmissions in patients with cirrhosis. Encephalopathy could be overt with obvious deterioration in the level of consciousness leading to hospitalizations, but could also be covert and less obvious to the patient and healthcare provider.

Covert hepatic encephalopathy (CHE) is often unrecognized by healthcare providers leading to falls, motor vehicular accidents, and potential progression to overt confusion. Progression of CHE to OHE makes recognition of this condition important as early identification and treatment can potentially improve quality of life, reduce hospital readmissions and healthcare costs. Existing diagnostic tools are not only tedious and time consuming, but also impacted by factors such as level of education, reducing their utility in clinical practice. The ideal test would be easy to use, quantifiable, quick, cheap, reliable, and able to predict outcomes.

The exploratory study will utilize a noninvasive computer application (Neurofit) that performs oculometric assessment of dynamic visual processing. Eye movements are short latency, voluntary motor behaviors that consist of various aspects including visual motion, pursuit initiation, steady-state tracking, direction tuning, and speed tuning. The computer application is based on an eye movement methodology that can quantify many aspects of human dynamic visual processing using a noninvasive video-based eye tracking technology with validated oculometric analysis techniques.

Prior studies have demonstrated sensorimotor dysfunction in patients with diffuse brain injury which leads to derangement in information processing throughout the brain. This computer application has been utilized in patients with traumatic brain injury (TBI). Liston et al, in a study of 34 TBI patients, demonstrated that TBI patients had several individual oculometrics that were significantly deranged including pursuit latency, initial pursuit acceleration, pursuit gain, catch-up saccade amplitude, proportion smooth tracking, and speed responsiveness as compared to a separate control group. The application was able to discriminate TBI subjects from controls with an 81% probability that increased with self-reported TBI severity.

Rationale Hepatic encephalopathy is believed to occur as a consequence of portosystemic shunting leading to toxins, octapamines, free fatty acids amongst others accumulating in the brain, causing impairment in neurocognitive functioning. The extent of brain dysfunction associated with hepatic encephalopathy has not been fully characterized. Hepatic encephalopathy could potentially impair global brain function leading to oculomotor discoordination that can be detected with this computer software. By comparing individual and composite oculometric data between patients with cirrhosis and those without cirrhosis this study may identify any significant differences or distinct patterns that may exist as a result of hepatic encephalopathy. For this study, covert hepatic encephalopathy will be determined by paper-based psychometric testing. Any data obtained from this feasibility/exploratory study, will serve as preliminary data for larger studies and future validation.

Being tested
Neurofit (oculometric testing)
Medical subject headings
Fibrosis, Hepatic Encephalopathy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Neurofit (oculometric testing)Device

    The Neurofit test involves sitting on a chair with a head and chin rest to maintain stability. Patients will then follow a moving object on the computer screen with their eyes which allows estimation of individual oculometrics along with a composite score. No physical contact or placement of invasive devices will be performed. The total time for completion of all the tests is estimated at 30 minutes.

Study groups in NCT04940416
Study groupRoleWhat they receive
CirrhosisThese will include patients with cirrhosis. They will perform the paper-based standard psychometric tests (number connection test A, number connection test B, line tracing test, and digital subtraction test, and serial dotting test, which take about 20 minutes). After completion of paper-based standard psychometric tests, participants will then perform the computer application test which takes about 5 minutes.
Receives: Device: Neurofit (oculometric testing)
Non-cirrhosisThese will include patients without cirrhosis seen in the general gastroenterology clinic. Participants will perform the paper-based standard psychometric tests (number connection test A, number connection test B, line tracing test, and digital subtraction test, and serial dotting test, which take about 20 minutes). After completion of paper-based standard psychometric tests, participants will then perform the computer application test which takes about 5 minutes.
Receives: Device: Neurofit (oculometric testing)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. NeuroFit score

    Composite oculometric test result

    Measured: at first visit (up to 5 minutes)

Secondary outcomes (1)
  1. Psychometric hepatic encephalopathy score

    Composite score from paper based psychometric test

    Measured: at first visit (up to 10 minutes)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Jun 2021
  2. Study start31 Aug 2017
  3. Primary completion17 Jun 2021
  4. Study completion17 Jun 2021

Why it stopped: Collaboration between partners ended, covid

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
48 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04940416
Sponsor's protocol ID
41796
Status last verified
Jun 2021
First submitted
17 Jun 2021
Last updated
25 Jun 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Cirrhosis and Hepatic Encephalopathy, run by Stanford University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 25 Jun 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: Collaboration between partners ended, covid). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

NeuroFit score (time frame: at first visit (up to 5 minutes)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jun 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in